SAN FRANCISCO, CA--(Marketwire - November 14, 2011) -
| Highlighted Links |
|
|
G. Steven Burrill, a biotech industry visionary and CEO of Burrill & Company, received the Breath of Life Award from the Northern California Chapter of the Cystic Fibrosis Foundation to honor him for his contributions to the life sciences industry throughout his career.
The Cystic Fibrosis Foundation honored Burrill during its Breath of Life Gala in San Francisco November 11. Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States. Established in 1955, the foundation has played an integral role in the development and U.S. Food and Drug Administration approval of four therapies that are now a routine part of treatment regimens for many with CF. The foundation is actively supporting more than 30 potential new treatments currently in development.
An early pioneer of the biotechnology industry, Burrill is one of its original architects and one of its most avid and sustained developers. The recognition from the Cystic Fibrosis Foundation follows Scrip Intelligence presenting Burrill with the Scrip Lifetime Achievement Award earlier this month.
“It has been my good fortune to have worked for more than 40 years within the biotech industry and contributed to companies tackling the greatest challenges facing our world today, from the development of drugs to treat diseases without adequate therapies to addressing the need to develop new and affordable sources of renewable energy,” says G. Steven Burrill. “I am honored to receive this recognition from an organization that has helped see that the advances of biotechnology have made it from the lab to the clinic where patients with serious medical needs have benefitted.”
Burrill currently serves as a member of the boards of directors of Catalyst Biosciences, Depomed, NewBridge Pharmaceuticals, Proventys, Targacept, and Expression Diagnostics. He previously served as Chairman of the Boards of Abunda Nutrition, BioImagene and Pharmasset.
Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm’s services to clients in the biotechnology, life sciences, high technology, and manufacturing industries worldwide.
Most recently, Burrill received the 2011 Scrip Lifetime Achievement Award for the contributions to the industry made throughout his career. In 2002, Scientific American magazine recognized Burrill as a biotech investment visionary naming him to The Scientific American 50. He has also been honored at the American Liver Foundation’s Annual “Salute to Excellence” Gala, which honors the best and the brightest from the San Francisco Bay Area’s medical, biotech, and biopharmaceutical industries. In 2008 he received the BayBio Pantheon DiNA lifetime achievement award for his worldwide biotech leadership.
In addition to his work with leading life science companies, Burrill is a founder and currently serves as chairman of the board of the National Science & Technology Medals Foundation. Additionally, he serves as chairman of the San Francisco Mayor’s Biotech Advisory Committee. Burrill also chaired the National Research Council study on linkages in biotechnology between Japan and the United States.
He was also involved with the U.S.-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the United States and Japan. Other not-for-profit activities include serving on the boards of directors of the Bay Area Science Infrastructure Consortium, BayBio (emeritus), California Healthcare Institute (emeritus), The Exploratorium (emeritus), The Kellogg Center for Biotechnology, the MIT Center for Biomedical Innovation, and the National Health Museum (vice chairman), World Council for Ethical Standards (chairman), Vilas County Economic Development Group (chairman), BIO Ventures for Global Health (BVGH), University of Wisconsin Extension, and the Scientific American Board of Advisors. He also serves on the editorial board of the Journal of Commercial Biotechnology and is on the advisory boards of the Center for Policy on Emerging Technologies, as well as BioAg Gateway, City of Madison.
He is an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin-College of Agriculture and Life Sciences, University of Minnesota College of Biological Sciences, and Duke University. He is also an adjunct professor at University of California, San Francisco.
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.
Contact:
Daniel Levine
Managing Director
Burrill & Company
Email Contact
415-591-5449
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
